Busse and Keilholz reported increased levels of TGF-β in melanoma patients with disease progression, providing an optimal microenvironment for undisturbed tumor growth by promoting tumor cell motility, invasiveness and modulating tumor stroma and extracellular matrix (Busse and Keilholz, 2011). This evidence concerns the gene TGFB1 and neoplasm.